Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cingulate Inc ( (CING) ).
On February 6, 2026, Cingulate Inc. issued 25,786 common shares at $6.16 each to a lender in exchange for a portion of outstanding debt, using an exemption from registration to strengthen its balance sheet by partially reducing liabilities through equity. On February 13, 2026, the company completed the second and final tranche of a private placement and appointed life sciences investor and former board member Jeff Hargroves as an independent Class I director and member of the audit, compensation, and nominating and governance committees, expanding investor representation on the board.
On February 17, 2026, Cingulate announced the closing of a $12 million PIPE financing, led by Falcon Creek Capital affiliates and priced at the January 26, 2026 Nasdaq closing share price of $5.04 with 80% warrant coverage and a 180-day lock-up for all investors, implying potential total proceeds of up to $21.4 million. The company said the capital will fund general operations as it advances toward the planned commercial launch of its ADHD candidate CTx-1301, subject to FDA approval, marking a key funding milestone that supports its near-term regulatory and commercialization objectives and tightens alignment between management, new institutional backers, and existing shareholders.
The most recent analyst rating on (CING) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Cingulate Inc stock, see the CING Stock Forecast page.
Spark’s Take on CING Stock
According to Spark, TipRanks’ AI Analyst, CING is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and sustained cash burn with ongoing financing needs). Technicals provide a partial offset due to strong recent momentum, though the stock looks stretched. Corporate events modestly help via added funding and NDA progress, while valuation remains constrained by unprofitability.
To see Spark’s full report on CING stock, click here.
More about Cingulate Inc
Cingulate Inc., based in Kansas City, Kan., is a biopharmaceutical company focused on developing next-generation treatments for ADHD and other central nervous system disorders. Its lead candidate, CTx-1301, a once-daily dexmethylphenidate tablet using the Precision Timed Release platform, is in commercial-stage development under the FDA’s 505(b)(2) pathway, with additional programs targeting anxiety and other neuropsychiatric conditions.
The company targets conditions where current therapies offer suboptimal therapeutic coverage and burdensome dosing schedules, aiming to deliver more consistent, all-day symptom control. Cingulate trades on Nasdaq under the ticker CING and positions itself within the life sciences sector as an innovator in extended-release and precisely timed pharmaceutical delivery technologies.
Average Trading Volume: 238,304
Technical Sentiment Signal: Buy
Current Market Cap: $46.43M
For an in-depth examination of CING stock, go to TipRanks’ Overview page.